Report date: Tuesday, August 4, 2026, before market open
Conference call: 7:30 a.m. ET
Share price: $115.25 as of August 3
Revvity enters the quarter with considerably higher expectations than it faced three months ago. The shares have risen roughly 33% since May 4, the session before the Q1 report, as investors embraced the planned divestiture of the China immunodiagnostics business, improving life-science demand trends and a credible margin-expansion story.
That makes this more than a simple beat-or-miss quarter. An in-line Q2 may not be enough unless management also confirms:
At $115.25, RVTY trades at approximately 22 times the midpoint of management’s 2026 adjusted EPS guidance. The valuation is not excessive if Revvity is moving toward sustainable mid-single-digit growth and continued margin expansion, but it leaves less room for execution problems than it did before Q1.
| Metric | Q2 2026 guidance |
|---|---|
| Pro forma revenue | $699 million–$707 million |
| Pro forma organic growth | 2%–3% |
| Pro forma adjusted operating margin | ~27% |
| Implied adjusted EPS | Approximately $1.20–$1.22 |
The EPS range is derived from management’s statement that Q2 should represent roughly 23% of its full-year adjusted EPS outlook of $5.20–$5.30.
For the full year, Revvity currently expects:
These figures are presented on a pro forma basis excluding the China immunodiagnostics operation Revvity plans to sell. Because the business has not yet closed, GAAP and reported figures may not align cleanly with the operational metrics investors should use.
Margin execution is probably the quarter’s most important financial test.
Pro forma adjusted operating margin was 24% in Q1, and management guided to approximately 27% in Q2, followed by roughly 29% in Q3. The Q1-to-Q2 increase was expected to come from:
The more consequential Q2-to-Q3 increase depends on cost-productivity actions scheduled to be fully implemented around midyear. Those initiatives include management delayering, workforce reductions, facility consolidation, sourcing, freight optimization and vendor renegotiation. Q1 restructuring actions affected approximately 2% of the workforce.
Investors should listen for explicit confirmation that the program is complete and producing the expected run-rate savings. A Q2 margin around 27% with continued confidence in the 29% Q3 target would support the earnings-growth thesis. A margin miss or delayed cost-out program would be much more concerning than a modest revenue shortfall.
Q1 showed the best pharma/biotech growth Revvity had experienced since the first half of 2023:
Management nevertheless remained cautious, describing customer behavior as measured and avoiding assumptions of a broad recovery.
For Q2, Revvity guided Life Sciences to be approximately flat, with Life Science Solutions growing in the low single digits. The key questions are therefore beneath the segment headline:
A continuation of positive reagent and instrument growth would strengthen the case that Revvity’s portfolio is outperforming the broader tools market.
Signals software is expected to decline approximately 20% organically in Q2, compared with unusually strong growth in the prior-year period. This will likely be the weakest-looking part of the release, but the reported revenue decline was clearly telegraphed.
The more informative metrics are:
In Q1, Revvity reported robust SaaS momentum, more than 30% ARR growth and double-digit growth in annualized portfolio value. Management expects software organic growth to rebound to the high teens in the second half, leaving the business at positive mid-single-digit growth for the full year.
Investors should focus on whether those forward indicators remain strong. A 20% revenue decline accompanied by healthy bookings and reiterated high-teens second-half growth would be benign. Weak ARR, lower bookings or a reduced second-half forecast would be a material negative.
Product commentary will also matter. Revvity is rolling out Xynthetica, BioDesign and, later this year, LabGistics as it positions Signals as an AI-enabled drug-discovery platform rather than a collection of traditional informatics products.
Management expects pro forma Diagnostics growth in the mid- to high-single digits, with similar growth from reproductive health and the remaining immunodiagnostics business.
Reproductive health grew in the low double digits in Q1, helped by:
Revvity continued to expect approximately $20 million of 2026 revenue from Genomics England, despite Q1 running ahead of its original volume assumptions. An increase to that estimate would provide upside, although investors should separate project revenue from the underlying reproductive-health growth rate.
Outside China, immunodiagnostics grew in the mid-single digits in Q1. Sustaining that pace would reinforce management’s argument that the China problem was localized and policy-driven rather than evidence of a broader competitive issue.
On April 16, Revvity signed a letter of intent to sell its China immunodiagnostics operation to a local management-led buyer group for up to $200 million. Its pro forma filing assumed potential consideration of approximately $140 million, excluding contingent consideration and including transferred liabilities.
On the May 5 earnings call, management expected a definitive agreement within roughly two months and anticipated closing in 2027 after manufacturing localization and regulatory approvals. As of August 3, Revvity had not publicly announced a definitive agreement.
Investors should therefore expect questions on:
The financial rationale remains compelling: excluding the business improved Q1 organic growth from 3% to 6%, lifted pro forma margin and removed a low-growth, lower-margin, cash-intensive operation. But continued transaction delays could reintroduce some of the uncertainty the announcement was intended to remove.
Q1 pro forma organic growth was 6%, well above the 3%–4% full-year target. Management noted that its second-half assumptions contained some conservatism and that stable or improving markets could produce upside.
The cleanest bullish outcome would be:
A simple reiteration would not necessarily be disappointing, but investors will want evidence that guidance remains prudent rather than increasingly dependent on a strong fourth quarter.
Tariffs increased Q1 cost of revenue by approximately $8 million, with a net gross-margin impact of about $6 million after mitigation. Revvity had not recognized potential tariff refunds at quarter-end because timing and recoverability remained uncertain.
Updates on refunds, pricing, supply-chain changes and manufacturing localization could influence the margin outlook.
Revvity entered Q2 with approximately $860 million of cash and expected to repay roughly $600 million of euro-denominated notes maturing in July. Investors should look for confirmation of repayment and the resulting leverage position.
The company also had approximately $800 million remaining under its share-repurchase authorization at the end of Q1. With the shares now materially higher, commentary on buyback activity and acquisition priorities will be informative.
A clearly positive result would likely include:
The principal downside scenarios are:
The Q2 headline numbers are relatively well framed: approximately $703 million of revenue, 2%–3% organic growth, a 27% adjusted operating margin and about $1.21 of adjusted EPS.
The more important question is whether Revvity can validate the next stage of its story. The stock’s rerating assumes that the company has removed its largest structural drag, that life-science demand is gradually normalizing, and that completed cost actions will drive a substantial second-half margin expansion.
A clean Q2 with strong underlying software metrics, stable end markets and confirmed cost execution should keep that thesis intact. Given the share-price appreciation since Q1, however, the best catalyst would be evidence that current full-year guidance is still conservative—along with concrete progress on the China divestiture.